DOW JONES NEWSWIRES -- Neurocrine Biosciences Inc. (NBIX) is selling a roughly 11% stake in the biopharmaceutical company to venture-capital firm Venrock at a 7.9% discount to Wednesday's closing price. The company will sell 4.8 million shares for $10 million, or $2.09 each; Neurocrine has some 39 million shares outstanding.
